https://www.selleckchem.com/pr....oducts/Sunitinib-Mal
Three months later she developed a subcutaneous mass at the site of the previous mastectomy. An ultrasound guided biopsy was carried out again and revealed a metastasis from CRC. The patient then started treatment with capecitabine plus bevacizumab, obtaining stable disease (RECIST criteria) and a clinical benefit after 3 mo of therapy. In our experience, capecitabine and bevacizumab may be a useful treatment option for breast metastases from primary CRC in elderly patients. In our experience, capecitabine and bevacizu
Curtir
Comentario
Compartilhar
